A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders

doi:10.1038/leu.2010.241

. 2011 Jan;25(1):184-6.

doi: 10.1038/leu.2010.241. Epub 2010 Oct 21.

A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders

K Yoshida, M Sanada, M Kato, R Kawahata, A Matsubara, J Takita, L-Y Shih, H Mori, H P Koeffler, S Ogawa

PMID: 20962861
PMCID: PMC5892825
DOI: 10.1038/leu.2010.241

A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders

K Yoshida et al. Leukemia. 2011 Jan.

. 2011 Jan;25(1):184-6.

doi: 10.1038/leu.2010.241. Epub 2010 Oct 21.

Authors

K Yoshida, M Sanada, M Kato, R Kawahata, A Matsubara, J Takita, L-Y Shih, H Mori, H P Koeffler, S Ogawa

PMID: 20962861
PMCID: PMC5892825
DOI: 10.1038/leu.2010.241

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors declare no conflict of interest.

Figures

**Figure 1**
Sequence of *IDH1* R100 mutation (case 9). The arrow indicates the mutated nucleotide.

See this image and copyright information in PMC

Cited by

Arginine CGA codons as a source of nonsense mutations: a possible role in multivariant gene expression, control of mRNA quality, and aging.
Romanov GA, Sukhoverov VS. Romanov GA, et al. Mol Genet Genomics. 2017 Oct;292(5):1013-1026. doi: 10.1007/s00438-017-1328-y. Epub 2017 May 18. Mol Genet Genomics. 2017. PMID: 28523359
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.
Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, Schnittger S, Sanada M, Kon A, Alpermann T, Yoshida K, Roller A, Nadarajah N, Shiraishi Y, Shiozawa Y, Chiba K, Tanaka H, Koeffler HP, Klein HU, Dugas M, Aburatani H, Kohlmann A, Miyano S, Haferlach C, Kern W, Ogawa S. Haferlach T, et al. Leukemia. 2014 Feb;28(2):241-7. doi: 10.1038/leu.2013.336. Epub 2013 Nov 13. Leukemia. 2014. PMID: 24220272 Free PMC article.
Mutations in epigenetic regulators in myelodysplastic syndromes.
Nikoloski G, van der Reijden BA, Jansen JH. Nikoloski G, et al. Int J Hematol. 2012 Jan;95(1):8-16. doi: 10.1007/s12185-011-0996-3. Epub 2012 Jan 11. Int J Hematol. 2012. PMID: 22234528 Review.
Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS.
Velegraki M, Stiff A, Papadaki HA, Li Z. Velegraki M, et al. J Clin Med. 2022 Aug 21;11(16):4908. doi: 10.3390/jcm11164908. J Clin Med. 2022. PMID: 36013147 Free PMC article. Review.
Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.
Lin TL, Nagata Y, Kao HW, Sanada M, Okuno Y, Huang CF, Liang DC, Kuo MC, Lai CL, Lee EH, Shih YS, Tanaka H, Shiraishi Y, Chiba K, Lin TH, Wu JH, Miyano S, Ogawa S, Shih LY. Lin TL, et al. Haematologica. 2014 Jan;99(1):28-36. doi: 10.3324/haematol.2013.091249. Epub 2013 Aug 30. Haematologica. 2014. PMID: 23996483 Free PMC article.

See all "Cited by" articles

References

1. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807–1812. - PMC - PubMed
1. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765–773. - PMC - PubMed
1. Thol F, Weissinger EM, Krauter J, Wagner K, Damm F, Wichmann M, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica. 2010;95:1668–1674. - PMC - PubMed
1. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17:225–234. - PMC - PubMed
1. Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia. 2010;24:1094–1096. - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

[1] Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807–1812. - PMC - PubMed

[2] Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807–1812. - PMC - PubMed

[3] Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765–773. - PMC - PubMed

[4] Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765–773. - PMC - PubMed

[5] Thol F, Weissinger EM, Krauter J, Wagner K, Damm F, Wichmann M, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica. 2010;95:1668–1674. - PMC - PubMed

[6] Thol F, Weissinger EM, Krauter J, Wagner K, Damm F, Wichmann M, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica. 2010;95:1668–1674. - PMC - PubMed

[7] Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17:225–234. - PMC - PubMed

[8] Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17:225–234. - PMC - PubMed

[9] Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia. 2010;24:1094–1096. - PubMed

[10] Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia. 2010;24:1094–1096. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders

A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders

Authors

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous